Core Insights - OXB achieved a significant revenue growth of 33% on a constant currency basis, reaching £170.9 million, and reported revenues increased by 31% to £168.7 million for the year ended 31 December 2025, demonstrating strong commercial momentum and operational execution [2][7][39] - The company reported an Operating EBITDA profit of £2.3 million, a substantial improvement from a loss of £15.3 million in 2024, driven by revenue growth and a focus on operating costs [7][39][79] - OXB's strategic execution included the acquisition of an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC, enhancing its capabilities in the growing cell and gene therapy market [3][25][59] Financial Performance - Revenue from manufacturing services increased by 18.6% to £81.1 million, while development services grew by 27.1% to £60.1 million, and procurement services surged by 284.5% to £22.3 million [5][71] - Gross profit rose by 23.8% to £66.0 million, with a gross margin of 39% [5][76] - The revenue backlog increased by approximately 36% to around £204 million, indicating strong future revenue visibility [7][41] Strategic Expansion - OXB's acquisition of the Durham facility for $4.5 million (£3.3 million) added significant manufacturing capabilities and supports late-stage client programs and commercial launches [25][39][59] - The company entered into a new multi-year Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors, further solidifying its market position [7][45] - OXB's global CDMO network expansion is supported by a new four-year term loan facility of up to $125 million with Oaktree Capital Management and an equity raise of approximately £60 million [24][66] Market Position and Outlook - The global cell and gene therapy pipeline grew to 2,251 candidates, reflecting a robust market environment that OXB is well-positioned to capitalize on [26][39] - OXB anticipates FY 2026 revenues between £220-240 million, with an expected Operating EBITDA margin of around 10% [14][36] - The company aims for medium-term revenue growth of 25-30% in FY 2027-2028, with EBITDA margins projected to rise to at least 20% in FY 2027 [7][14] Innovation and Technology - OXB continues to focus on innovation, enhancing its viral vector manufacturing capabilities and integrating advanced technologies such as mass spectrometry and AI for process optimization [28][49][51] - The establishment of the Innovation and Technology Excellence Board aims to drive strategic investments in scalable technologies, ensuring OXB remains at the forefront of scientific advancement [29][39] Governance and ESG Initiatives - OXB strengthened its governance framework with new board appointments and incorporated ESG-linked key performance indicators into annual bonus arrangements, reflecting its commitment to sustainability [30][34] - The company achieved a reduction in operational emissions by over 6% and advanced its social responsibility agenda through enhanced employee engagement initiatives [32][33]

Core Insights - OXB has entered into a licensing and option agreement with VVMF, Australia's first commercial manufacturing facility for viral vectors, to enhance its global reach in cell and gene therapy [1][2][4] Group 1: Agreement Details - The agreement grants VVMF a worldwide, non-exclusive license to OXB's inAAVate™ platform and an option for the LentiVector™ platform, with OXB receiving a low single-digit million license fee and potential future payments [2][3] - This five-year license aims to accelerate VVMF's operational and commercial readiness, focusing on the growing demand in the APAC region [3][4] Group 2: Strategic Implications - The collaboration reinforces OXB's position as a trusted provider of viral vector development and manufacturing services, highlighting the scalability and reliability of its platforms [4][5] - VVMF aims to leverage OXB's expertise to establish a leadership position in the APAC region, enhancing its operational capabilities and aligning with industry standards [6][5] Group 3: Company Background - OXB is a pioneer in cell and gene therapy with 30 years of experience in viral vectors, collaborating with leading pharmaceutical and biotechnology companies [9][12] - The company offers a range of technologies for viral vector manufacturing, including advanced systems for lentiviral and AAV production [10][9]